FSSAI bars non-compliant drinks from using 'ORS' label after 8-year doctor-led campaign
October 2025 ruling restricts the ORS label to drinks matching WHO formulation, forcing reformulation, repackaging or rebranding across pharmacy and beverage shelves. Decision follows Hyderabad paediatrician Dr Sivaranjani Santosh's sustained advocacy and reshapes a category long dominated by sugary look-alikes.
What happened
FSSAI ruled in October 2025 that packaged drinks not meeting WHO-recommended ORS formulation cannot use the term ORS on labels, following an eight-year campaign
Key facts
- October 2025
Why this matters
Watch for distressed divestitures of non-compliant beverage lines and acquisition windows on small WHO-compliant ORS brands as the category consolidates around the protected label.
What to watch
- FSSAI enforcement notices or seizure reports in Q4 2025 / Q1 2026
- Reformulation or rename announcements from JNTL (ORSL), Kissan, Dabur, Himalaya
- Court challenges or stay orders from beverage manufacturers
- IAP or WHO India follow-on advocacy targeting glucose-water and 'energy' drinks
- Pharmacy chain (Apollo, MedPlus, Tata 1mg) delisting actions
- New entrants in WHO-compliant ORS with D2C or premium positioning
- Audit own-label and private-label hydration SKUs for ORS/ORSL nomenclature exposure within 30 days
- Lock supply of WHO-compliant ORS sachets from compliant manufacturers (FDC, Cipla, TTK) ahead of pharmacy-channel demand spike
- Re-plan beverage planograms: separate clinical ORS shelf (pharmacy-adjacent) from sugary electrolyte drinks in cooler
- Brief marketing/legal on permissible claims; pre-clear new pack copy with FSSAI advisory
- Engage paediatrician and IAP networks for co-branded education on genuine ORS — converts regulatory shift into trust equity